An update on the use of atripla® in the treatment of HIV in the United States

HIV/AIDS - Research and Palliative Care

Volumn 2, Issue , 2010, Pages 135-140

  Horberg, Michael A ^a   Klein, Daniel B ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

Antiretroviral therapy; Efavirenz; Emtricitabine; Tenofovir

Indexed keywords

EID: 77954560090     PISSN: None     EISSN: 11791373     Source Type: Journal    
DOI: 10.2147/hiv.s6366     Document Type: Article

References (69)

1. Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS. 2003;17(13):1925-1932.
2. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21-30.
3. Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007;4(2):65-72.
4. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS. 2003;17(4):169-177.
5. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000;30 SUPPL 2:S171-S176.
6. Flexner C, Tierney C, Gross R, et al. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS Clinical Trials Group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis. 1;50(7):1041-1052.
7. Simoni JM, Frick PA, Pantalone DW, Turner BJ. Antiretroviral adherence interventions: a review of current literature and ongoing studies. Top HIV Med. 2003;11(6):185-198.
8. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001;15(11):1369-1377.
9. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341(25):1865-1873.
10. Corales RB, Shrestha NK, Taege AJ, et al. Protease-sparing regimen in a real-life practice with naive patients: an equal opportunity approach? HIV Clin Trials. 2001;2(1):17-21.
11. Knechten H, Sturner KH, Hohn C, Braun P. Switch to efavirenz in a protease inhibitor-containing regimen. HIV Clin Trials. 2001;2(3):200-204.
12. US Food and Drug Administration. Antiretroviral drugs used in the treatment of HIV infection. 2010. Available from: http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/hivandaidsactivities/ ucm118915.htm Accessed Apr 1, 2010.
13. Dando TM, Wagstaff AJ. Emtricitabine/tenofovir disoproxil fumarate. Drugs. 2004;64(18):2075-2082; discussion 2083-2074.
14. Frampton JE, Croom KF. Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet. Drugs. 2006;66(11):1501-1512; discussion 1513-1504.
15. Mathias AA, Hinkle J, Menning M, Hui J, Kaul S, Kearney BP. Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen. J Acquir Immune Defic Syndr (1999). 2007;46(2):167-173.
16. Bristol-Myers Squibb and Gilead Sciences Inc. Atripla (efavirenz/ emtricitabine/tenofovir disoproxil furmarate) Prescribing Information 2010.
17. Frampton JE, Perry CM. Emtricitabine: a review of its use in the management of HIV infection. Drugs. 2005;65(10):1427-1448.
18. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defici Syndr (1999). 2008;47(1):74-78.
19. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. New Engl J Med. 2006;354(3):251-260.
20. Horberg MTB, Towner W, Bersoff-Matcha S, et al. Two Versus Three Pill HAART Does it Make a Difference? [Oral abstract 44]. 3rd IAPAC/ NIMH Conference on HIV Treatment Adherence. Jersey City, NJ, 2008.
21. Bartlett JA, Chen SS, Quinn JB. Comparative efficacy of nucleoside/ nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview. HIV Clin Trials. 2007;8(4):221-226.
22. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. New Engl J Med. 2009;361(23):2230-2240.
23. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. In: Department of Health and Human Services, editor. Department of Health and Human Services; 2009:1-161.
24. Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(5):651-681.
25. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2009 Dec. Top HIV Med. 2009;17(5): 138-145.
26. Rhee SY, Kantor R, Katzenstein DA, et al. HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. AIDS. 2006;20(5):643-651.
27. Manfredi R, Rizzo E, Calza L, Chiodo F. The use of efavirenz as a part of late rescue antiretroviral treatment. HIV Clin Trials. 2001;2(5):413-420.
28. Campo RE, Lichtenberger PN, Rosa I, et al. Differences in the frequency of resistance to antiretroviral drug classes among human immunodeficiency virus type 1 clinical isolates. J Clin Microbiol. 2003;41(7):3376-3378.
29. Buskin SE, Torno MS, Talkington DF, et al. Trends in nephropathy among HIV-infected patients. J Natl Med Assoc. 2009;101(12):1205-1213.
30. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40(11):1559-1585.
31. Colebunders R, Vanwolleghem T, Meurrens P, Moerman F. Efavirenz-associated Stevens-Johnson syndrome. Infection. 2004;32(5): 306-307.
32. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Int Med. 2005;143(10):714-721.
33. Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother. 2009;64(5):910-928.
34. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet. 2004;43(15):1071-1087.
35. Shlay JC, Sharma S, Peng G, Gibert CL, Grunfeld C. The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr (1999). 2009;51(3):298-304.
36. Matthews GV, Seaberg E, Dore GJ, et al. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS. 2009;23(13):1707-1715.
37. Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis. 2009;48(12):1763-1771.
38. Nunez M, Perez-Olmeda M, Diaz B, Rios P, Gonzalez-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS (London, England). 2002;16(17):2352-2354.
39. van Bommel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology (Baltimore, Md). 2010;51(1):73-80.
40. Elzi L, Marzolini C, Furrer H, et al. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med. 2010;170(1):57-65.
41. Perez-Molina JA. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trials. 2002;3(4):279-286.
42. Zaccarelli M, Soldani F, Liuzzi G, et al. CNS side effects as main risk factor for efavirenz failure and transient HIV-RNA elevation [abstract 720]. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington, USA: Foundation for Retrovirology and Human Health, Alexandria, Virginia, USA; 2002.
43. Fumaz CR, Munoz-Moreno JA, Molto J, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr (1999). 2005;38(5):560-565.
44. Shikuma CM, Yang Y, Glesby MJ, et al. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr. 2007;44(5):540-550.
45. von Giesen HJ, Koller H, de Nocker D, Haslinger BA, Arendt G. Longterm safety and efficacy of NNRTI within the central nervous system. HIV Clin Trials. 2003;4(6):382-390.
46. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007;21(10):1273-1281.
47. Perazella MA. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci. 2003;325(6):349-362.
48. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr. 2004;35(3):269-273.
49. Callens S, De Roo A, Colebunders R. Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir. J Infect. 2003;47(3):262-263.
50. Earle KE, Seneviratne T, Shaker J, Shoback D. Fanconi's syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res. 2004;19(5):714-721.
51. Gaspar G, Monereo A, Garcia-Reyne A, de Guzman M. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution. AIDS. 2004;18(2):351-352.
52. Malik A, Abraham P, Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment case report and review of literature. J Infect. 2005;51(2):E61-E65.
53. Quimby D, Brito MO. Fanconi syndrome associated with use of tenofovir in HIV-infected patients: a case report and review of the literature. AIDS Read. 2005;15(7):357-364.
54. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002;40(6):1331-1333.
55. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197(1):102-108.
56. Fux CA, Simcock M, Wolbers M, et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther. 2007;12(8):1165-1173.
57. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191-201.
58. Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr. 2004;37(4):1489-1495.
59. Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant. 2005;20(4):743-746.
60. Antoniou T, Raboud J, Chirhin S, et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med. 2005;6(4):284-290.
61. Padilla S, Gutierrez F, Masia M, Canovas V, Orozco C. Low frequency of renal function impairment during one-year of therapy with tenofovircontaining regimens in the real-world: a case-control study. AIDS Patient Care STDS. 2005;19(7):421-424.
62. Young B, Buchacz K, Baker RK, et al. Renal function in tenofovirexposed and tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV outpatient study. J Int Assoc Physicians AIDS Care (Chic Ill). 2007;6(3):178-187.
63. Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS. 2008;22(16):2155-2163.
64. Horberg M, Tang B, Towner W, et al. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr (1999). 2010;53(1):62-69.
65. Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS. 2008;22(2):99-103.
66. Cassetti I, Madruga JV, Suleiman JM, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials. 2007;8(3):164-172.
67. Jimenez-Nacher I, Garcia B, Barreiro P, et al. Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. J Antimicrob Chemother. 2008;62(4):816-822.
68. Innovaro Pharmalicensing. Sales of antiretroviral agents will drive substantial six percent annual growth in the HIV drug market through 2013. 2009. Available from: http://pharmalicensing.com/public/press/ view/1244103588_4a2783a4c60b2/ Accessed Apr 1, 2010.
69. Dejesus E, Young B, Morales-Ramirez JO, et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr (1999). 2009;51(2):163-174.